Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 13Breast Neoplasms 11Carcinoma, Transitional Cell 6Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 3Small Cell Lung Carcinoma 2Urothelial Bladder Carcinoma 1Salivary Gland Neoplasms 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Lung Diseases 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1Liver Failure 1HRD Cancer 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Small Cell 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Nivolumab 2sacituzumab govitecan 1relatlimab 1pembrolizumab 1erdafitinib 1enfortumab vedotin 1avelumab 1Vinblastine 1Specimen Handling 1Paclitaxel 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Cystoscopy 1Cisplatin 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle Invasive Bladder Urothelial Carcinoma × sacituzumab govitecan × 90 days × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡